Research
Hormonal
Glucagon-like peptide-1 (GLP-1) receptor agonists, such as exenatide, promote progressive weight loss in humans over up to two years while improving glycemic control, distinguishing them from other diabetes treatments that often cause weight gain.
GLP-1 receptor agonists are a highly effective treatment for both diabetes and obesity. They work by mimicking a gut hormone that signals fullness to the brain. Unlike many other diabetes drugs, they help patients lose weight progressively over time.
StrongSupportsVERY_HIGH confidence
patients with diabetes treated with either GLP1 or the GLP1 receptor (GLP1R) agonist exenatide lose weight progressively in trials lasting up to two years.
Why this rating
Cited clinical trials show progressive weight loss over two years.
Source
Gastrointestinal regulation of food intake
David E. Cummings et al. · Journal of Clinical Investigation · 2007
narrative_reviewCited 1,196×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →